Publicaciones en las que colabora con Alfonso Jesús Domínguez-Gil Hurlé (58)

2009

  1. Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients

    Journal of Pharmacy and Pharmacology, Vol. 61, Núm. 6, pp. 759-766

2004

  1. Pharmacokinetic basis for the use of extended interval dosage regimens of gentamicin in neonates

    Journal of Antimicrobial Chemotherapy, Vol. 54, Núm. 1, pp. 193-198

1999

  1. Population pharmacokinetics of amikacin in patients with haematological malignancies

    Journal of Antimicrobial Chemotherapy, Vol. 44, Núm. 2, pp. 235-242

1998

  1. Influence of clinical diagnosis in the population pharmacokinetics of amikacin in intensive care unit patients

    Clinical Drug Investigation, Vol. 15, Núm. 5, pp. 435-444

1997

  1. Population pharmacokinetics of caffeine in premature neonates

    European Journal of Clinical Pharmacology, Vol. 52, Núm. 3, pp. 211-217

  2. Study on pharmacokinetics and nephrotoxicity of netilmicin in rabbits using a new dosage regimen

    Methods and Findings in Experimental and Clinical Pharmacology, Vol. 19, Núm. 1, pp. 53-59

1996

  1. Bayesian forecasting in paediatric populations

    Clinical Pharmacokinetics

  2. Influence of pharmacokinetic model on vancomycin peak concentration targets

    Therapeutic Drug Monitoring, Vol. 18, Núm. 2, pp. 145-148

  3. Pharmacokinetics of amikacin in intensive care unit patients

    Journal of Clinical Pharmacy and Therapeutics, Vol. 21, Núm. 6, pp. 417-421

1995

  1. Binding of roxithromycin to total plasma proteins, albumin, polymorphonuclear cells and lymphocytes

    Revista Espanola de Quimioterapia, Vol. 8, Núm. 1, pp. 46-50

  2. Determination of netilmicin in plasma by HPLC

    Journal of Pharmaceutical and Biomedical Analysis, Vol. 13, Núm. 8, pp. 1059-1062

  3. Uptake of antibiotics by phagocytic cells: Study methods and therapeutic implications

    Revista Espanola de Quimioterapia, Vol. 8, Núm. 2, pp. 100-108

1992

  1. A method for the calculation of bioavailability in slow release formulations in the presence of within-individual variability

    International Journal of Pharmaceutics, Vol. 86, Núm. 2-3, pp. 123-130

  2. LIMITACIONES ANALITICAS EN LA MONITORIZACION DE NIVELES SERICOS DE DIGOXINA

    Farmacia Clinica, Vol. 9, Núm. 9, pp. 774-785

1991

  1. Bioequivalence of a new formulation of flecainide acetate.

    European journal of drug metabolism and pharmacokinetics, Vol. Spec No 3, pp. 216-220

1990

  1. Effect of renal impairment on distribution of ofloxacin

    Antimicrobial Agents and Chemotherapy, Vol. 34, Núm. 3, pp. 455-459

  2. Evolución histórica de la biofarmacia y farmacocinética, una nueva disciplina farmacéutica

    Industria farmacéutica: Equipos, procesos y tecnología, Núm. 2, pp. 151-156

  3. Influence of a single dose of ethanol on the kinetics of valproic acid in rats

    Drug Metabolism and Disposition, Vol. 18, Núm. 5, pp. 732-734

  4. Optimization of dosage regimens of aminoglycoside antibiotics in the presence of beta-lactam agents by simulation techniques

    Acta Pharmaceutica Jugoslavica, Vol. 40, Núm. 2 SUPPL. 1, pp. 301-308

1989

  1. MODIFICACIONES EN LA CINETICA DEL CLOBAZAM EN MODELO EXPERIMENTAL DE ALCOHOLISMO CRONICO

    Ciencia e Industria Farmaceutica, Vol. 8, Núm. 10-12, pp. 238-241